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ABSTRAK 
 
Genom manusia mengandungi banyak variasi genetik submikroskopik dari segi 
salinan nombor; ini termasuk delesi, duplikasi dan insersi. Walaupun analisis 
kromosom melalui teknik kariotip masih digunakan sebagai ujian utama dalam 
penyiasatan pesakit dismorfisma yang juga mengalami masalah terencat akal, 
teknologi molekular seperti hibridasi genomik perbandingan barisan (array 
comparative genomic hybridisation, aCGH) terbukti sensitif dan boleh dipercayai 
dalam mengenalpasti variasi genetik submikroskopik ini. Seorang bayi berumur tiga 
bulan dirujuk kerana masalah dismorfisma, mikrokefali dan rencatan perkembangan 
global. Ujian kariotip pertama adalah normal. Walaubagaimanapun, keputusan ini 
adalah berdasarkan kualiti metafasa yang kurang memuaskan. Ujian aCGH telah 
mengenalpasti delesi bersaiz 30.6Mb pada kromosom 5p15.33-p13.3. Kes ini 
menunjukkan keberkesanan aCGH sebagai ujian makmal bagi mengenalpasti 
masalah ketidakseimbangan kromosom. 
 
Kata kunci:  array comparative genomic hybridization, aCGH; kerencatan akal; 
sindrom cri-du-chat 
 
 
ABSTRACT  
 
The human genome contains many submicroscopic copy number variations which 
includes deletions, duplications and insertions. Although conventional karyotyping 
remains an important diagnostic tool in evaluating a dysmorphic patient with mental 
retardation, molecular diagnostic technology such as array comparative genomic 
hybridization (aCGH) has proven to be sensitive and reliable in detecting these 
submicroscopic anomalies. A 3 month-old infant with dysmorphic facies, microcephaly 
and global developmental delay was referred for genetic evaluation. Preliminary 
karyotyping which was confounded by the quality of metaphase spread was normal; 
however, aCGH detected a 30.6Mb deletion from 5p15.33-p13.3. This case illustrates 
the usefulness of aCGH as an adjunctive investigative tool for detecting chromosomal 
imbalances. 
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INTRODUCTION  
 
Dysmorphism associated with develop-
mental delay or mental retardation is a 
common indication for chromosomal 
analysis. Although the underlying aetiol-
ogy may only be recognized in ~40 to 
60% of cases, there is a need to obtain 
an accurate diagnosis as this will affect 
overall management in terms of coun-
seling for recurrence and prognosis 
(Manning et al. 2007). Recent studies 
using array comparative genomic hybri-
dization (aCGH) have shown that dele-
tions and duplications are causative in 8 
to 17% of such cases (Manning et al. 
2007). We report an infant with craniofa-
cial dysmorphism and global develop-
mental delay who was diagnosed to have 
a terminal chromosomal deletion follow-
ing aCGH. 
 
CASE REPORT  
 
A 3 month-old infant was referred for fa-
cial dysmorphism. The antenatal period 
was uneventful and she was born term 
via normal delivery. She was small for 
gestational age with birth weight 2.17kg. 
Her parents were non-consanguinous. 
She was admitted for neonatal jaundice 
at day 6 of life; newborn screening for 
hearing via otoacoustic emission (OAE) 
was abnormal. Follow-up with brainstem 
evoked response (BSER) revealed bila-
teral sensorineural hearing loss. Clini-
cally she was microcephalic and had fail-
ure to thrive. She had fair skin pigmenta-
tion. The ears were simple; there was 
hypertelorism and she had a high nasal 
bridge. Her nose was short; the lips were 
thin and the corners of her mouth were 
downturned (Figure 1). Her fingers were 
clenched and she had bilateral clinodac-
tyly. There was also feeding difficulty i.e. 
she had swallowing incoordination and 
there was global developmental delay. 
MRI brain showed microcephaly with 
evidence of white matter volume loss and 
cerebral atrophy suggestive of perinatal 
ischaemic insult. Screening for inborn 
errors of metabolism was negative and 
the preliminary conventional karyotyping 
(of 4 metaphase spreads) was reported 
as normal. In view of the craniofacial 
dysmorphism and global developmental 
delay, blood was sent for aCGH. The in-
vestigation revealed a 30.6Mb deletion at 
5p15.33-13.3 (Figure 2) which was con-
firmed by fluorescence-in-situ hybridiza-
tion (FISH) using the Vysis LSI 
EGR1/D5S23, D5S721 Dual Color Probe 
as shown in Figure 3. 
 
 
DISCUSSION 
 
Chromosomal analysis is often requested 
as a first-line investigation in a child with 
mental retardation, multiple congenital 
malformation and dysmorphism. Based 
on data from published research, mental 
retardation affects approximately 3% of 
the general population; of these, less 
than 50% have an identifiable cause of 
which 40% is attributable to chromo-
somal anomaly (Manning et al. 2007).  In 
a review by Sharkey et al. 2005, 0.8% of 
liveborn infants have chromosomal ano-
malies of whom half are associated with 
an abnormal phenotype (Sharkey et al. 
2005). With conventional moderate level 
karyotyping (at 400 to 500 banding), the 
detection rate of chromosomal anomalies 
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Figure 1: Frontal view of the patient 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Array CGH revealed a 30.6Mb deletion at 
5p15.33-13.3 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Interphase FISH analysis using the Vysis 
LSI EGR1/D5S23, D5S721 Dual Color Probe 
shows one (1) green and two (2) orange signal 
pattern, indicating the deletion of one 5p15.2 
region. The 5p15.2 region (D5S23, D5S721) is 
labelled with SpectrumGreen-dUTP while the EGR1 
region is labelled with SpectrumOrange-dUTP. 
is 13.3%; 3.8% was for structural and 
7.8% for numerical anomalies (Sharkey 
et al. 2005). 
In general, both conventional and 
spectral karyotyping (SKY) is unreliable 
in detecting copy number changes of 
less than 5Mb (Bar-Shira et al. 2006). 
Array CGH is a high resolution, whole 
genome based technology that has a 
better diagnostic detection rate of these 
submicroscopic chromosomal aberra-
tions underlying patients with multiple 
anomaly syndromes; a resolution of 
≤1Mb and up to 35kb has been reported 
(Manning et al. 2007 & Bar-Shira et al. 
2006). With aCGH, metaphase spreads 
are replaced by cloned (bacterial artificial 
chromosomes, BACs) or synthesized 
(oligonucleotides) DNA fragments across 
the genome that are immobilized on a 
glass surface, the exact chromosomal 
locus of which is known (Manning et al. 
2007). Both sample and control DNA are 
then hybridized onto the DNA fragments 
spotted onto the array; copy number 
variations are then measured via com-
puter analysis based on the diferrences 
in hybridization pattern intensities.  
With aCGH, the detection rate of un-
balanced chromosomal rearrangements 
has been shown to be between 10% to 
24% (Bar-Shira et al. 2006). At present, 
there are two types of array platform: 
constitutional or targeted array, and 
whole genome array (Manning et al. 
2007 & Baldwin et al. 2008). The tar-
geted approach incorporates common 
microdeletion or duplication syndromes, 
telomeric regions and centromeres and 
selected Mendelian disorders (Baldwin et 
al. 2008). The development of such a 
custom made array has been likened to 
performing a ‘6000 band karyotype’. 
Whereas, a whole genome array has a 
wider coverage over the human genome. 
When first introduced, the whole genome 
array contained ~2400 BAC clones dis-
tributed over the genome; the newer 
generation of arrays are now even more 
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dense. The resolution of aCGH is limited 
by the size and distance between the 
DNA fragments that are spotted onto the 
array (Manning et al. 2007). In a series 
by Baldwin et al. 2008, the genome-wide 
array coverage identified an additional 
4.7% of clinically significant abnormalities 
that would not be detected by current 
targeted array platform. The average size 
of imbalances was ~3.7Mb and con-
tained an average of 17 known genes 
(Baldwin et al. 2008).  In this study, ar-
ray-based CGH analysis was performed 
using commercially available oligonuc-
leotide microarrays containing about 244, 
000 60-mer probes with an average res-
olution of about 8.9 kb (Human Genome 
CGH Microarray 244A kit, Agilent Tech-
nologies). The deletion was subsequently 
revealed by the use of array-based CGH, 
a molecular cytogenetic technique with 
an extremely high resolution. All these 
data confirm the importance of perform-
ing a more sophisticated investigation in 
patients in whom a complex phenotype is 
strongly suggestive of the presence of a 
chromosomal aberration; indeed, aCGH 
is a powerful technique for identifying 
chromosomal rearrangements where 
conventional cytogenetics has failed. 
Reports of aCGH in identifying cytoge-
netic abnormalities missed by routine 
cytogenetic analyses have been reported 
in the literature and further support the 
sensitivity of aCGH (Shafer et al. 2006). 
In our patient, initial karyotyping was re-
ported as normal; interpretation was 
however made based on a limited num-
ber of metaphase spreads, as correctly 
cited by the laboratory. The issue of ob-
taining an adequate number of meta-
phase spreads occurs every now and 
then; this may be the result of insufficient 
volume of blood extracted which is not 
uncommon amongst paediatric patients 
particularly. Application of other molecu-
lar technique such as Multiplex Ligation 
Probe-dependant Amplification (MLPA) 
method can improve resolution for detec-
tion of changes in DNA copy number but 
it is typically applied in a targeted manner 
that assesses one or several candidate 
loci at a time which limit the detection 
rate in syndromic cases. Thus, aCGH 
was subsequently requested following 
the ‘normal’ karyotype as the patient was 
seen to be very ‘chromosomal’, a state-
ment often concluded by clinical gene-
ticists. The latter investigation indeed 
eluded the underlying chromosomal 
anomaly which was subsequently con-
firmed by FISH analysis. FISH analysis is 
the recommended method for validating 
aCGH studies; furthermore, FISH is not 
only cost-effective but also has the ad-
vantage of demonstrating the mechanism 
of the imbalance (Baldwin et al. 2008). 
Cri-du-chat syndrome is a relatively 
rare syndrome and affects between 1 in 
40 000 to 50 000 live births (Cornish et 
al. 1999). The basic defect is due to a 
partial deletion, either terminal or intersti-
tial, of 5p15.2-p15.3. Although the name 
of the syndrome is derived from the high-
pitched, shrill cry heard in a larger series 
of patients, the cry is neither pathogno-
monic nor present in all patients. This 
anomaly is largely de novo (~85%) but 
may be the result of an unbalanced 
translocation inherited from either parent 
(Gorlin et al. 2001). In our patient, a 
30.6Mb deletion was detected at 
5p15.33-p13.3; of the 54 genes that 
spanned this region, 10 have been re-
ported in association with clinical disord-
ers. However, two of the latter have been 
identified to be the most significant; this 
was the CTNDD2 gene and SDHA gene 
which are associated with Cri-du-chat 
syndrome and Leigh syndrome. Pheno-
typically, our patient showed features 
consistent with the former syndrome. Pa-
rental karyotyping and aCGH were nor-
mal, thus the deletion was de novo. Pre-
natal diagnosis with FISH using uncul-
tured amniocytes have been successfully 
reported in cases where the chromo-
somal anomaly is the result of a parent 
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being a balanced translocation carrier 
(Gorlin et al. 2001 & McKusick-Nathans 
Institute of Genetic Medicine 2010). 
As anticipated, the larger the deletion, 
the more severe the phenotype. In addi-
tion to both somatic and mental retarda-
tion, patients with 5p deletion exhibit the 
following clinical features:  microcephaly, 
increased inner canthal distance (75%), 
down-slanting palpebral fissures (60%), 
epicanthic folds, broad nasal bridge with 
prominent nasal root and a round face. 
Marked hypotonia and feeding difficulties 
are common as seen in our patient. 
Other major malformations include: con-
genital heart defects (30-50%), muscu-
loskeletal and central nervous system 
anomalies [eg hypoplastic cerebellum, 
corpus callosum dysgenesis and arach-
noid cyst] (Gorlin et al. 2001 & McKusick-
Nathans Institute of Genetic Medicine 
2010). The MRI brain of our patient 
showed no specific structural anomaly; 
she is presently on a multidisciplinary 
follow-up which involves regular 
monitoring by the developmental Paedia-
trician and Clinical Geneticist, rehabilita-
tion by occupational therapy, physiothe-
rapy and speech therapy, in addition to 
serial evaluation by audiology and oph-
thalmology. 
Although aCGH is increasingly used as 
a diagnostic tool in patients with global 
developmental delay, one of the main 
drawbacks is its potential for identifying 
novel copy number variations that may 
not be responsible for the patient’s global 
delay. Even if a variant is present in the 
affected individual but absent from “nor-
mal” parental genomes, it does not nec-
essarily follow that it is a pathogenetic 
change, and it may instead represent an 
innocuous copy-number polymorphism (a 
normal variation in the human genome). 
Interpretation of aCGH is often a chal-
lenging process; to facilitate this process, 
several international databases have 
been established; these include DECI-
PHER (Database of Chromosomal Im-
balance and Phenotype in Humans Us-
ing Ensemble Resources, 
http://www.sanger.ac.uk/PostGenomics/d
ecipher/) and ECARUCA, the European 
Cytogeneticists Association Register of 
Unbalanced Chromosome Aberrations 
(http://www.ecaruca.net/). In a meta-
analysis by Subramonia-Iyer et al. (2007) 
involving seven studies amongst patients 
with learning disabilities, an acceptable 
false-positive rate (for non-causal ab-
normalities) of between 5 to 10% was 
reported (Subramonia-Iyer et al. 2007).  
 
CONCLUSION 
 
Array CGH is a sensitive tool in detecting 
submicroscopic chromosomal aberra-
tions that are undetectable by current 
cytogenetic tests. However, before being 
accepted as a routine diagnostic evalua-
tion, certain issues pertaining to both 
clinical and laboratory aspects should be 
considered. These include the selection 
of patient phenotype, optimal array res-
olution and appropriateness of array 
platform, establishment of quality assur-
ance in a clinical set-up, availability of 
genetic counseling and of course, cost-
effectiveness as compared to existing 
genetic tests. 
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